Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omacetaxine + Azacitidine + G-CSF in Relapsed/Refractory MDS
NCT02835794Phase 2Withdrawn
- Sponsor
- University of Florida
- Start
- Aug 2016
- Primary completion
- Dec 2018
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of homoharringtonine in myelodysplastic syndrome (MDS), sponsored by University of Florida. Planned start Aug 2016; status: withdrawn.
02
Drugs
homoharringtonine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02835794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02835794.